Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00402077 · ClinicalTrials.gov registry record · Phase 2

A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

A Phase 2 study of Obesity and Overweight, sponsored by AstraZeneca.

Completed
Registry status
Phase 2
Development phase
258
Enrollment target
16
Study locations

NCT00402077 is a Phase 2 study of Obesity and Overweight that has completed, run by AstraZeneca. The registered enrollment target is 258 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (68% lower). The trial reports 16 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00402077, a Phase 2 study of Obesity and Overweight, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 2
Development phase
258 participants
Enrollment target
16
Study locations

Study Summary

This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects.

Conditions Studied

Obesity Overweight

Interventions

  • DRUG placebo
  • DRUG pramlintide acetate
  • DRUG sibutramine
  • DRUG phentermine

Study Locations (16)

California

  • Research Site - Chula Vista
  • Research Site - La Jolla
  • Research Site - Los Angeles
  • Research Site - Walnut Creek

Florida

  • Research Site - Miami
  • Research Site - Pembroke Pines

North Carolina

  • Research Site - Raleigh
  • Research Site - Statesville

Texas

  • Research Site - Austin
  • Research Site - San Antonio

Alabama

  • Research Site - Birmingham

Arizona

  • Research Site - Phoenix

Kentucky

  • Research Site - Louisville

New York

  • Research Site - New York

Trial Details

FieldValue
Enrollment Target 258 participants
Start Date 2006-11
Est. Completion 2007-08
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00402077

The ClinicalTrials.gov registry entry for NCT00402077 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 258 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (68% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which placebo is the first listed.

NCT00402077 reports 16 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, North Carolina.

Frequently Asked Questions

What is clinical trial NCT00402077 about?

NCT00402077 is a clinical study titled "A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects". This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects.

What is the current status of trial NCT00402077?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 258 participants. The study started on 2006-11. Estimated completion is 2007-08.

What conditions does trial NCT00402077 study?

This clinical trial studies the following conditions: Obesity, Overweight.

What interventions are being tested in trial NCT00402077?

The interventions under investigation include: placebo (DRUG), pramlintide acetate (DRUG), sibutramine (DRUG), phentermine (DRUG).

Who is sponsoring clinical trial NCT00402077?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00402077 being conducted?

This trial has 16 study locations across Alabama, Arizona, California, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Overweight

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.